What is Poxel?
Poxel is dedicated to advancing novel therapies for liver and rare metabolic disorders. The company's pipeline is complemented by royalty revenue from a partnered diabetes treatment commercialized in Japan. This strategic positioning in the biopharmaceutical sector, particularly within metabolic diseases, highlights a commitment to addressing significant unmet medical needs.
How much funding has Poxel raised?
Poxel has raised a total of $71.4M across 6 funding rounds:
Series A
$21M
Series B
$13.5M
Share Placement
$19.4M
Unspecified
$7M
Debt
$6.1M
Other Financing Round
$4.3M
Series A (2010): $21M with participation from Edmond de Rothschild
Series B (2014): $13.5M, investors not publicly disclosed
Share Placement (2020): $19.4M supported by Undisclosed
Unspecified (2020): $7M featuring Bpifrance and BNP Paribas
Debt (2022): $6.1M backed by IRIS
Other Financing Round (2026): $4.3M with participation from IPF Partners
Key Investors in Poxel
Bpifrance
Bpifrance is a French public investment bank that finances companies across all stages of development, supporting innovation and international expansion.
BNP Paribas
BNP Paribas is a leading international banking group offering a wide range of financial services, including corporate and institutional banking, investment solutions, and retail banking.
IPF Partners
IPF Partners is a specialized healthcare financing provider offering tailored debt and equity solutions to commercial-stage companies in the biopharma, digital health, and medtech sectors.
What's next for Poxel?
The recent major strategic investment suggests Poxel is poised for significant scaling and further clinical development. This infusion of capital will likely accelerate its pipeline progression, potentially enabling Poxel to advance its lead candidates through late-stage trials and expand its research into new therapeutic areas. The company's focus on metabolic dysfunction positions it to capitalize on growing market demand for effective chronic disease management solutions.
See full Poxel company page
